Arrowhead Research
Corporation (NASDAQ: ARWR), a nanotechnology company commercializing new
technologies in the areas of life sciences, electronics, and energy, today announced
that Scientific Advisory Board members Mauro Ferrari, Ph.D., and Chad Mirkin,
Ph.D., were featured in the July 2009 editions of both Nature Medicine and Nature
magazines for their outstanding work in nanomedicine.
The Nature article, titled, "Big opportunities in a small world,"
may be viewed at: www.nature.com/naturejobs/2009/090723/full/nj7254-540a.html.
An excerpt from the Nature Medicine article, titled, "Straight talk with...
Mauro Ferrari," may be viewed at www.nature.com/nm/journal/v15/n7/full/nm0709-716.html.
The complete article is also available for purchase.
"Drs. Mirkin and Ferrari are true pioneers in nanomedicine and we are
honored to benefit from their expertise through their deep involvement with
our company," said Arrowhead President and CEO Chris Anzalone. "Working
closely with such leaders is a critical piece of our business model. The fact
that they are both featured in high impact journals in a single month is a real
tribute to their contributions to science."
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanotechnology company
commercializing new technologies in the areas of life sciences, electronics,
and energy. Arrowhead is seeking to build value for shareholders through the
progress of majority owned subsidiaries. Currently, Arrowhead has four subsidiaries
commercializing nanotech products and applications and minority investments
in two privately held nanobiotech companies.
Posted July 31st, 2009
